Original Article

You have full text access to this OnlineOpen article

Ferritin ferroxidase activity: A potent inhibitor of osteogenesis

  1. Abolfazl Zarjou1,
  2. Viktória Jeney1,
  3. Paolo Arosio2,
  4. Maura Poli2,
  5. Erzsébet Zavaczki1,
  6. György Balla3,
  7. József Balla1,*

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.091002

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 1, pages 164–172, January 2010

Additional Information

How to Cite

Zarjou, A., Jeney, V., Arosio, P., Poli, M., Zavaczki, E., Balla, G. and Balla, J. (2010), Ferritin ferroxidase activity: A potent inhibitor of osteogenesis. J Bone Miner Res, 25: 164–172. doi: 10.1359/jbmr.091002

Author Information

  1. 1

    Department of Medicine, University of Debrecen, 4012 Debrecen, Hungary

  2. 2

    Dipartimento Materno Infantile e Tecnologie Biomediche, University of Brescia, Brescia, Italy

  3. 3

    Department of Pediatrics, University of Debrecen, Debrecen, Hungary

*19, Nagyerdei krt. 98, 4032 Debrecen, Hungary.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 14 DEC 2009
  3. Manuscript Accepted: 9 OCT 2009
  4. Manuscript Revised: 12 AUG 2009
  5. Manuscript Received: 30 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (317K)

References

  • 1
    Angelopoulos NG, Goula AK, Papanikolaou G, Tolis G. Osteoporosis in HFE2 juvenile hemochromatosis: a case report and review of the literature. Osteoporosis Int. 2006; 17: 150–155.
  • 2
    Guggenbuhl P, Deugnier Y, Boisdet JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporosis Int. 2005; 16: 1809–1814.
  • 3
    Schnitzler CM, Schnaid E, MacPhail AP, Mesquita JM, Robson HJ. Ascorbic acid deficiency, iron overload and alcohol abuse underlie the severe osteoporosis in black African patients with hip fractures: a bone histomorphometric study. Calcif Tissue Int. 2005; 76: 79–89.
  • 4
    Weinberg ED. Iron loading: a risk factor for osteoporosis. Biometals. 2006; 19: 633–635.
  • 5
    Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996; 1275: 161–203.
  • 6
    Theil EC. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem. 1996; 56: 289–315.
  • 7
    Arosio P, Adelman TG, Drysdale JW. On ferritin heterogeneity: further evidence for heteropolymers. J Biol Chem. 1978; 253: 4451–4458.
  • 8
    Rucker P, Torti FM, Torti SV. Role of H and L subunits in mouse ferritin. J Biol Chem. 1996; 271: 33352–33357.
  • 9
    Hentze MW, Rouault TA, Caughman SW, Dancis A, Harford JB, Klausner RD. A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. Proc Natl Acad Sci USA. 1987; 84: 6730–6734.
  • 10
    Casey JL, Hentze MW, Koeller DM, et al. Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science. 1988; 240: 924–928.
  • 11
    Broxmeyer HE, Cooper S, Levi S, Arosio P. Mutuated recombinant human heavy-chain ferritins and myelosuppression in vitro and in vivo: a link between ferritin ferroxidase activity and biological function. Proc Natl Acad Sci USA. 1991; 88: 770–774.
  • 12
    Yang X, Chen-Barrett Y, Arosio P, Chasteen ND. Reaction paths of iron oxidation and hydrolysis in horse spleen and recombinant human ferritins. Biochemistry. 1998; 37: 9743–9750.
  • 13
    Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radicals Biol Med. 2001; 31: 509–519.
  • 14
    Buckwalter JA, Glimcher MJ, Cooper RR, Recker R. Bone biology. I: Structure, blood supply, cells, matrix, and mineralization. Instr Course Lect. 1996; 45: 371–386.
  • 15
    Buckwalter JA, Glimcher MJ, Cooper RR, Recker R. Bone biology. II: Formation, form, modeling, remodeling, and regulation of cell function. Instr Course Lect. 1996; 45: 387–399.
  • 16
    Baslé MF, Mauras Y, Audran M, Clochon P, Rebel A, Allain P. Concentration of bone elements in osteoporosis. J Bone Miner Res. 1990; 5: 41–47.
  • 17
    Diamond T, Pojer R, Stiel D, Alfrey A, Posen S. Does iron affect osteoblast function? Studies in vitro and in patients with chronic liver disease. Calcif Tissue Int. 1991; 48: 373–379.
  • 18
    Duquenne M, Rohmer V, Legrand E, et al. Spontaneous multiple vertebral fractures revealed primary haemochromatosis. Osteoporosis Int. 1996; 6: 338–340.
  • 19
    Sinigaglia L, Fargion S, Fracanzani AL, et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol. 1997; 24: 1809–1813.
  • 20
    Van de Vyver FL, Vanheule AA, Majelyne WM, et al. Serum ferritin as a guide for iron stores in chronic hemodialysis patients. Kidney Int. 1984; 26: 451–458.
  • 21
    de Vernejoul MC, Pointillart A, Golenzer CC, et al. Effects of iron overload on bone remodeling in pigs. Am J Pathol. 1984; 116: 377–384.
  • 22
    Matsushima S, Hoshimoto M, Torii M, Ozaki K, Narama I. Iron lactate–induced osteopenia in male Sprague-Dawley rats. Toxicol Pathol. 2001; 29: 623–629.
  • 23
    Cornish J, Callon KE, Naot D, et al. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology. 2004; 145: 4366–4374.
  • 24
    Naot D, Grey A, Reid IR, Cornish J. Lactoferrin: a novel bone growth factor. Clin Med Res. 2005; 3: 93–101.
  • 25
    Chen CH, Ho ML, Chang JK, Hung SH, Wang GJ. Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. Osteoporosis Int. 2005; 16: 2039–2045.
  • 26
    Christoforidis A, Kazantzidou E, Tsatra I, et al. Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassaemia major. Hormones. 2007; 6: 334–340.
  • 27
    Tyler PA, Madani G, Chaudhuri R, Wilson LF, Dick EA. The radiological appearances of thalassaemia. Clin Radiol. 2006; 61: 40–52.
  • 28
    Rioja L, Girot R, Garabédian M, Cournot-Witmer G. Bone disease in children with homozygous beta-thalassemia. Bone Miner. 1990; 8: 69–86.
  • 29
    Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ. Low bone mineral density in adolescents with beta-thalassemia. Ann NY Acad Sci. 2005; 1054: 462–466.
    Direct Link:
  • 30
    Brill PW, Winchester P, Giardina PJ, Cunningham-Rundles S. Deferoxamine-induced bone dysplasia in patients with thalassemia major. AJR, Am J Roentgenol. 1991; 156: 561–565.
  • 31
    Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992; 267: 18148–18153.
  • 32
    Beazley KE, Nurminskaya M, Talbot CJ, Linsenmayer TF. Corneal epithelial nuclear ferritin: developmental regulation of ferritin and its nuclear transporter ferritoid. Dev Dyn. 2008; 237: 2529–2541.
    Direct Link:
  • 33
    Surguladze N, Patton S, Cozzi A, Fried MG, Connor JR. Characterization of nuclear ferritin and mechanism of translocation. Biochem J. 2005; 388: 731–740.
  • 34
    Thompson KJ, Fried MG, Ye Z, Boyer P, Connor JR. Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei. J Cell Sci. 2002; 5: 2165–2177.
  • 35
    Broyles RH, Belegu V, DeWitt CR, et al. Specific repression of beta-globin promoter activity by nuclear ferritin. Proc Natl Acad Sci USA. 2001; 98: 9145–9150.
  • 36
    Zhao G, Arosio P, Chasteen ND. Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin: an EPR spin-trapping study. Biochemistry. 2006; 45: 3429–3436.
  • 37
    Poole LB, Nelson KJ. Discovering mechanisms of signaling-mediated cysteine oxidation. Curr Opin Chem Biol. 2008; 12: 18–24.
  • 38
    Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. Arterioscler Thromb Vasc Biol. 1997; 17: 680–687.
  • 39
    Byon CH, Javed A, Dai Q, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem. 2008; 283: 15319–15327.
  • 40
    Zarjou A, Jeney V, Arosio P, et al. Ferritin prevents calcification and osteoblastic differentiation of vascular smooth muscle cells. J Am Soc Nephrol. 2009; 20: 1254–1263.
View Full Article (HTML) Get PDF (317K)